Trial Profile
A randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of DDP225 in patients with chronic functional vomiting
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 09 Dec 2014
Price :
$35
*
At a glance
- Drugs DDP 225 (Primary)
- Indications Vomiting
- Focus Therapeutic Use
- Sponsors Dynogen Pharmaceuticals
- 26 Apr 2008 New trial record.